Skip to content

US · CNTB · BIOTECHNOLOGY

Connect Biopharma Holdings Limited (CNTB) intrinsic value and stock valuation

$0.59as of 2026-11-21 · Mkt cap 137.26M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Connect Biopharma Holdings Limited DCF and intrinsic value

InvestorsCraft values CNTB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CNTB’s statements →

Connect Biopharma Holdings Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 connectbiopharma.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$60K
20192025
Net income
-$-55.48M
20192025
Free cash flow
-$-51.64M
20192025
Total equity
$42M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$60K$26M$0.00$0.00$0.00
Operating income-$-58.07M-$-22.45M-$-69.06M-$-119.32M-$-98.11M
Net income-$-55.48M-$-15.63M-$-62.11M-$-118.09M-$-202.27M
EPSd-$-996.77K-$-283.1K-$-1.13M-$-2.15M-$-3.87M
Operating cash flow-$-51.21M-$-23.61M-$-47.93M-$-99.27M-$-85.57M
Capital expenditure-$-430K-$-750K-$-290K-$-4.28M-$-7.46M
Free cash flow-$-51.64M-$-24.36M-$-48.22M-$-103.55M-$-93.03M
Total assets$56.1M$101.3M$127.4M$174M$291.1M
Total debt$690K$180K$470K$430K$120K
Net debt-$-37.66M-$-78.05M-$-105.2M-$-78.58M-$-267.59M
Total equity$42M$92.2M$101.5M$157.5M$272.3M
Cash and short-term investments$44.3M$93.7M$118.3M$152.4M$267.7M
Income statement
20252024202320222021
Revenue$60K$26M$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$60K$26M$0.00$0.00$0.00
Research and development expenses$37.8M$29.3M$53M$96.6M$80.5M
Selling, general and administrative expenses$20.3M$19.2M$16.1M$20.8M$19M
Other expenses$0.00$0.00$0.00$1.88M-$-1.4M
Operating expenses$58.1M$48.5M$69.1M$119.3M$98.1M
Cost and expenses$58.1M$48.5M$69.1M$119.3M$98.1M
Interest income$2.27M$4.45M$10K$1.56M$100K
Interest expense$0.00$0.00$0.00$20K$10K
Depreciation and amortization$700K$660K$720K$1.03M$630K
Ebitda-$-54.58M-$-14.74M-$-61.27M-$-116.74M-$-201.36M
Operating income-$-58.07M-$-22.45M-$-69.06M-$-119.32M-$-98.11M
Total other income/expenses, net$2.79M$7.05M$7.07M$1.52M-$-103.89M
Income before tax-$-55.28M-$-15.4M-$-61.99M-$-117.79M-$-202M
Income tax expense$200K$220K$120K$300K$270K
Net income-$-55.48M-$-15.63M-$-62.11M-$-118.09M-$-202.27M
Weighted average shares outstanding$55.7M$55.2M$55.1M$55M$52.3M
Weighted average diluted shares outstanding$55.7M$55.2M$55.1M$55M$52.3M
Balance sheet
20252024202320222021
Cash and short-term investments$44.3M$93.7M$118.3M$152.4M$267.7M
Net receivables$160K$1.05M$350K$230K$7.41M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$50.9M$97M$122.6M$155.8M$275.1M
Property, plant and equipment, net$4.46M$4.24M$4.74M$5.38M$9.44M
Goodwill and intangible assets$40K$50K$60K$3.17M$3.54M
Long-term investments$0.00$0.00$0.00$9.44M$0.00
Total non-current assets$5.15M$4.32M$4.82M$18.2M$15.9M
Total assets$56.1M$101.3M$127.4M$174M$291.1M
Accounts payable$1.96M$340K$2.21M$11.9M$12.7M
Short-term debt$320K$150K$280K$190K$100K
Deferred revenue$170K$160K$13.3M$0.00$0.00
Total current liabilities$13.6M$8.46M$25.3M$15.6M$18M
Long-term debt$370K$20K$180K$240K$30K
Deferred revenue, non-current$0.00$0.00$410K$650K$780K
Total non-current liabilities$480K$660K$580K$900K$810K
Capital lease obligations$690K$180K$470K$430K$120K
Total liabilities$14.1M$9.12M$25.9M$16.5M$18.8M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-400.83M-$-345.36M-$-329.73M-$-479.84M-$-361.75M
Accumulated other comprehensive income (loss)-$-1.19M-$-1.67M-$-1.01M-$-7.63M-$-4.03M
Total equity$42M$92.2M$101.5M$157.5M$272.3M
Total investments$6M$15.5M$12.6M$82.9M$0.00
Total debt$690K$180K$470K$430K$120K
Net debt-$-37.66M-$-78.05M-$-105.2M-$-78.58M-$-267.59M
Cash flow statement
20252024202320222021
Net income-$-55.48M-$-15.63M-$-59.38M-$-116.12M-$-204.94M
Depreciation and amortization$700K$660K$990K$1.01M$640K
Stock-based compensation$3.73M$6.73M$3.26M$1.01M$1.41M
Change in working capital$580K-$-15.49M$9.48M$7.16M$3.27M
Accounts receivable$780K-$-790K$1.04M$0.00-$0.00
Inventory$0.00$0.00$0.00-$0.00$0.00
Accounts payable$1.62M-$-1.87M-$-4.28M$380K$8.89M
Net cash provided by operating activities-$-51.21M-$-23.61M-$-47.93M-$-99.27M-$-85.57M
Investments in property, plant and equipment-$-430K-$-750K-$-290K-$-4.28M-$-7.46M
Acquisitions, net$0.00$0.00$2.94M$80K$50K
Net cash used for investing activities$9.82M-$-3.45M$75.2M-$-83.44M-$-5.34M
Common stock issued$1.09M$230K$40K$20K$220M
Common stock repurchased$0.00$0.00$0.00$0.00-$-570K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.09M$230K-$-250K-$-90K$206.7M
Net change in cash-$-39.89M-$-27.43M$27M-$-168.93M$109.4M
Cash at end of period$38.3M$78.2M$106M$80.4M$268M
Operating cash flow-$-51.21M-$-23.61M-$-47.93M-$-99.27M-$-85.57M
Capital expenditure-$-430K-$-750K-$-290K-$-4.28M-$-7.46M
Free cash flow-$-51.64M-$-24.36M-$-48.22M-$-103.55M-$-93.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Connect Biopharma Holdings Limited

        Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

        CEO
        Barry D. Quart
        Employees
        64
        Beta
        -0.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Connect Biopharma Holdings Limited (CNTB)?

        InvestorsCraft does not currently publish an intrinsic value for CNTB. How the IC value is calculated.

        Is CNTB undervalued?

        InvestorsCraft does not publish an undervaluation signal for CNTB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.